Company intelligence / Profile preview

Harmony Biopharm

Plymouth Meeting, Pennsylvania, United States

Ownership: Private
Employees: ~268
Development stage: Other

Overview

WAKIX (pitolisant) is FDA-approved for excessive daytime sleepiness in adult and pediatric narcolepsy patients (ages 6+), and for cataplexy in adult narcolepsy patients. The company reported net product revenues of $714.7 million for full year 2024, with projected revenues between $820-860 million for 2025.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Bioprojet (exclusive license for pitolisant)

Beyond the preview

Go deeper on Harmony Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harmony Biopharm.

Explore the full profile